NCT06081166View on ClinicalTrials.gov

A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

November 11, 2023

Primary Completion Date

December 2, 2023

Study Completion Date

January 22, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

Obicetrapib

obicetrapib 10 mg daily

DRUG

Atorvastatin Calcium

Atorvastatin 80 mg

DRUG

Rosuvastatin Calcium

Rosuvastatin 40 mg

Trial Locations (1)

M1S 3V6

Mark M Feldman, Toronto

Sponsors
All Listed Sponsors
collaborator

Pharma Medica Research, Inc.

INDUSTRY

lead

NewAmsterdam Pharma

INDUSTRY